跳至主要内容
临床试验/DRKS00033562
DRKS00033562招募中未知

A prospective non-randomized controlled trial testing the efficacy of psychotherapeutic inpatient treatment of Post-COVID-19 syndrome

Psychosomatische und Psychotherapeutische Abteilung, Universitätsklinikum Erlangen0 个研究点目标入组 60 人开始时间: 2024年2月15日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1)PCR-confirmed SARS-Cov-2 infection and subsequent PASC: complaints that are still present more than 12 weeks after the onset of SARS-Cov-2 infection and cannot be explained otherwise
  • 2)Written informed consent to participate in the study
  • 3)Sufficient knowledge of the German language to participate in the study
  • 4)Treatment group: indication for inpatient psychosomatic treatment due to:
  • -A clinically relevant psychiatric diagnosis
  • -Limitations that significantly reduce the ability to manage everyday life (e.g. the ability to maintain daily structure)
  • -Subjective stress so great that the quality of life and everyday resilience are significantly limited
  • 5)Control group: depressive symptoms in self-assessment (PHQ-9 = 10)

排除标准

  • -Severely physically impaired patients (predominantly bedridden)
  • -Unique or main diagnosis of substance abuse (F10 – F19), schizophrenia, psychosis (F20 – F229) or organic psychiatric disorders (F00 – F09)
  • -Suicidality
  • -Control group: utilization of PASC-specific outpatient or inpatient psychotherapeutic treatment or psychosomatic rehabilitation during 5 weeks of treatment

研究者

发起方
Psychosomatische und Psychotherapeutische Abteilung, Universitätsklinikum Erlangen

相似试验

A prospective non-randomized controlled trial... | 临床试验